Vor Bio opts to keep manufacturing operations in-house for developing stem cell, CAR-T therapies

Date Published09/29/2022
Author NameTyler Patchen
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Vor Biopharma
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2022
City reshored to:Cambridge
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredhematopoietic stem cells (eHSCs), CAR-T therapies
What domestic positive factors made reshoring more attractive?Skilled workforce availability/training
Find Reshoring Articles